Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription Articles published in Nat Rev Clin Oncol Retrieve available abstracts of 19 articles: HTML format

Single Articles

February 2026
1. KILLOCK D
   CDK4/6 inhibition provides additional efficacy in HER2(+), HR(+) breast cancer.
   Nat Rev Clin Oncol. 2026 Feb 17. doi: 10.1038/s41571-026-01133.
   PubMed    
   
   
   
2. LOBO-MARTINS S, Luen SJ, Piccart M, Loi S, et al
   Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.
   Nat Rev Clin Oncol. 2026 Feb 3. doi: 10.1038/s41571-026-01120.
   PubMed     Abstract available
   
   
   November 2025
3. KILLOCK D
   T-DXd shows promise in neoadjuvant therapy for HER2(+) breast cancer.
   Nat Rev Clin Oncol. 2025 Nov 10. doi: 10.1038/s41571-025-01103.
   PubMed    
   
   
   
4. FEHM T, Neubauer H
   Intervening on dormancy to prevent breast cancer recurrence.
   Nat Rev Clin Oncol. 2025 Nov 3. doi: 10.1038/s41571-025-01087.
   PubMed    
   
   
   August 2025
5. KILLOCK D
   ASTER 70 suggests no clinical benefit from adjuvant chemotherapy in older patients with ER(+)HER2(-) breast cancer.
   Nat Rev Clin Oncol. 2025 Aug 18. doi: 10.1038/s41571-025-01070.
   PubMed    
   
   
   July 2025
6. NEVEN P, Han SN
   PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER(+)HER2(-) breast cancer harbouring acquired ESR1 mutations.
   Nat Rev Clin Oncol. 2025 Jul 22. doi: 10.1038/s41571-025-01062.
   PubMed    
   
   
   June 2025
7. CARLETON N, McAuliffe PF
   Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring.
   Nat Rev Clin Oncol. 2025 Jun 9. doi: 10.1038/s41571-025-01040.
   PubMed    
   
   
   
8. ROBBINS CJ, Bates KM, Rimm DL
   HER2 testing: evolution and update for a companion diagnostic assay.
   Nat Rev Clin Oncol. 2025;22:408-423.
   PubMed     Abstract available
   
   
   January 2025
9. SIDAWAY P
   Women with clinically node negative breast cancer can safely avoid axillary surgery.
   Nat Rev Clin Oncol. 2025 Jan 3. doi: 10.1038/s41571-024-00982.
   PubMed    
   
   
   November 2024
10. KILLOCK D
    First-line triplet therapy for advanced-stage PIK3CA-mutant HR(+) breast cancer improves outcomes.
    Nat Rev Clin Oncol. 2024 Nov 12. doi: 10.1038/s41571-024-00968.
    PubMed    
    
    
    
11. DRAGO J, Modi S
    Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
    Nat Rev Clin Oncol. 2024 Nov 6. doi: 10.1038/s41571-024-00963.
    PubMed    
    
    
    
12. WAKS AG, Martinez-Saez O, Tarantino P, Braso-Maristany F, et al
    Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.
    Nat Rev Clin Oncol. 2024;21:818-832.
    PubMed     Abstract available
    
    
    August 2024
13. LLOYD MR, Jhaveri K, Kalinsky K, Bardia A, et al
    Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.
    Nat Rev Clin Oncol. 2024 Aug 23. doi: 10.1038/s41571-024-00935.
    PubMed     Abstract available
    
    
    
14. MARRA A, Chandarlapaty S, Modi S
    Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
    Nat Rev Clin Oncol. 2024 Aug 2. doi: 10.1038/s41571-024-00933.
    PubMed    
    
    
    July 2024
15. YOON J, Oh DY
    HER2-targeted therapies beyond breast cancer - an update.
    Nat Rev Clin Oncol. 2024 Jul 22. doi: 10.1038/s41571-024-00924.
    PubMed     Abstract available
    
    
    June 2024
16. KILLOCK D
    ALND can be safely omitted for patients with sentinel-node macrometastases.
    Nat Rev Clin Oncol. 2024;21:402.
    PubMed    
    
    
    May 2024
17. DIECI MV, Guarneri V
    Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain.
    Nat Rev Clin Oncol. 2024 May 22. doi: 10.1038/s41571-024-00907.
    PubMed    
    
    
    April 2024
18. SIDAWAY P
    KN046 shows tolerability and activity in TNBC.
    Nat Rev Clin Oncol. 2024;21:251.
    PubMed    
    
    
    March 2024
19. KONTOS D
    The promise of AI in personalized breast cancer screening: are we there yet?
    Nat Rev Clin Oncol. 2024 Mar 12. doi: 10.1038/s41571-024-00877.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum